• Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
Menu
  • Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
  • September 10, 2021
  • 2021 Abstracts

Real world data to evaluate the efficacy and safety of intravitreal aflibercept injections for the treatment of macular oedema secondary to Retinal Vein Occlusions (RVO)

Author: Amey Tamhane (United Kingdom)

Co-authors: Paritosh Shah, Brinda Shah, Emmanuel Lakidi

Purpose

Real world data to evaluate the efficacy and safety of intravitreal aflibercept injections for the treatment of macular oedema secondary to Retinal Vein Occlusions (RVO).

Setting/Venue

Retrospective interventional non-randomized clinical study done at Yeovil District Hospital & NHS Foundation Trust between June 2016 to February 2021.

Methods

160 eyes of 160 treatment naïve patients with macular oedema secondary to retinal vein occlusion (73 eyes Branch retinal vein occlusion (BRVO), 80 eyes Central Retinal Vein Occlusion (CRVO) and 7 eyes Hemi Retinal Vein Occlusion (HRVO) treated with intravitreal 2.0 mg Aflibercept injections between June 2016 to February 2021 were included in the study. All the patients received 2 loading dose injections, after which Treat & Extend (T&E) regimen was followed. The primary efficacy end points were, improvement in best-corrected visual acuity (BCVA) from baseline and reduction in Central Retinal Thickness(CRT).

Results

We had a slight female preponderance (51.25 %) with a median age of 76 years. Patients received a median of 8 injections in BRVO eyes, (range 4 to 26) 9 injections (range 3 to 32) in CRVO eyes and 5 (range 2 to 8) injections in HRVO eyes. Median BCVA improved in all patients from baseline to T&E : 35 to 65 letters, 60 to 75 letters and 47.5 to 75 letters in CRVO, BRVO & HRVO eyes respectively and maintained subsequently. 43.13% (69 eyes) gained 15 or more ETDRS letters. Median CRT reduced significantly : CRVO (596 um vs 287.5 um), BRVO (457 um vs 292 um) and HRVO (449 um vs 289 um). 9.37% (15 eyes) had recurrence of disease activity while on T&E regimen and needed long term treatment to maintain the improvement.

Conlusions

Treatment with intravitreal aflibercept provided significant functional and anatomic benefits for all types of retinal vein occlusions. It was well tolerated and none of the patients on treatment developed neovascular complications. Some eyes needed long term treatment to maintain the visual gains.

Financial Disclosure

NONE

Comments

-

Secretariat Address
European Society of Retina Specialists
Ground Floor, The Apex Building 
Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2

Phone:+353 1 2100092
Email: [email protected]

EURETINA 2022 Hamburg

Opportunities

Memberships

Forum

About

Privacy Policy

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2021 All rights reserved
  • Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login